One year versus a shorter duration of adjuvant trastuzumab for HER2-positive early breast cancer: a systematic review and meta-analysis

被引：0
|
作者：
Alessandro Inno
Sandro Barni
Antonio Ghidini
Alberto Zaniboni
Fausto Petrelli
机构：
[1] IRCCS Ospedale Sacro Cuore Don Calabria,Oncology Unit, Cancer Care Center
[2] ASST Bergamo Ovest,Oncology Unit, Medical Sciences Department
[3] Casa di Cura Igea,Oncology Unit
[4] Casa di Cura Poliambulanza,Oncology Unit
来源：
Breast Cancer Research and Treatment | 2019年 / 173卷
关键词：
Breast cancer; Adjuvant; Trastuzumab; Duration; One year;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：247 / 254
页数：7
相关论文
共 50 条
  • [21] Trastuzumab biosimilars vs trastuzumab originator in the treatment of HER2-positive breast cancer: a systematic review and network meta-analysis
    Liu, Tong
    Liu, Duo
    Jin, Yao
    Dong, Mei
    [J]. IMMUNOPHARMACOLOGY AND IMMUNOTOXICOLOGY, 2022, 44 (06) : 809 - 815
  • [22] Adjuvant Trastuzumab in HER2-Positive Breast Cancer
    Slamon, Dennis
    Eiermann, Wolfgang
    Robert, Nicholas
    Pienkowski, Tadeusz
    Martin, Miguel
    Press, Michael
    Mackey, John
    Glaspy, John
    Chan, Arlene
    Pawlicki, Marek
    Tamas Pinter
    Valero, Vicente
    Liu, Mei-Ching
    Sauter, Guido
    von Minckwitz, Gunter
    Visco, Frances
    Bee, Valerie
    Buyse, Marc
    Bendahmane, Belguendouz
    Tabah-Fisch, Isabelle
    Lindsay, Mary-Ann
    Riva, Alessandro
    Crown, John
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2011, 365 (14): : 1273 - 1283
  • [23] Adjuvant trastuzumab for HER2-positive breast cancer
    Spicer, J
    Harries, M
    Ellis, P
    [J]. LANCET, 2005, 366 (9486): : 634 - 634
  • [24] Duration of trastuzumab for HER2-positive breast cancer
    Montemurro, Filippo
    Aglietta, Massimo
    [J]. LANCET ONCOLOGY, 2013, 14 (08): : 678 - 679
  • [25] Benefits of adjuvant treatment including trastuzumab in HER2-positive pT1a-bNOMO breast cancer: a systematic review and meta-analysis
    Lee, Hye Yoon
    Shin, In-Soo
    Rim, Chai Hong
    [J]. ANNALS OF TRANSLATIONAL MEDICINE, 2020, 8 (05)
  • [26] Short-duration versus 1-year adjuvant trastuzumab in early HER2 positive breast cancer: A meta-analysis of randomized controlled trials
    Chen, Lujia
    Zhou, Wenqi
    Hu, Xiaolei
    Yi, Man
    Ye, Changsheng
    Yao, Guangyu
    [J]. CANCER TREATMENT REVIEWS, 2019, 75 : 12 - 19
  • [27] HER2 amplification level is not a prognostic factor for HER2-positive breast cancer with trastuzumab-based adjuvant treatment: a systematic review and meta-analysis
    Xu, Qian-Qian
    Pan, Bo
    Wang, Chang-Jun
    Zhou, Yi-Dong
    Mao, Feng
    Lin, Yan
    Guan, Jing-Hong
    Shen, Song-Jie
    Zhang, Xiao-Hui
    Xu, Ya-Li
    Zhong, Ying
    Wang, Xue-Jing
    Zhang, Yan-Na
    Sun, Qiang
    [J]. ONCOTARGET, 2016, 7 (39) : 63571 - 63582
  • [28] Trastuzumab in the Adjuvant Treatment of HER2-Positive Early Breast Cancer Patients: A Meta-Analysis of Published Randomized Controlled Trials
    Yin, Wenjin
    Jiang, Yiwei
    Shen, Zhenzhou
    Shao, Zhimin
    Lu, Jinsong
    [J]. PLOS ONE, 2011, 6 (06):
  • [29] Clinical therapeutic effects of trastuzumab in HER2-positive breast cancer patients A protocol for systematic review and meta-analysis
    Tong, Chuanming
    Wang, Chuan
    Yang, Kun
    [J]. MEDICINE, 2021, 100 (17) : E25685
  • [30] Role of trastuzumab in the adjuvant treatment of HER2-positive early breast cancer
    Haq, Bushra
    Geyer, Charles E.
    [J]. WOMENS HEALTH, 2009, 5 (02) : 135 - 147
12345